Renal disease and kidney function
ENYO Pharma’s clinical research includes studies in Alport syndrome and in participants with impaired renal function, with attention to kidney-related outcomes in settings where renal decline is a major concern.
- Alport syndrome
- Renal impairment
- Kidney safety
The sponsor’s renal portfolio is centered on conditions where preservation of glomerular filtration and monitoring of renal tolerability are clinically important.
Metabolic liver disease
The company also studies suspected MASH, focusing on patients who present with metabolic and renal comorbidity and where liver-related disease burden intersects with reduced kidney function.
- MASH
- Metabolic dysfunction-associated steatohepatitis
- Hepatorenal involvement
This area reflects interest in therapeutic approaches relevant to metabolic liver disease alongside renal assessment.
Healthy volunteer pharmacology
ENYO Pharma includes healthy volunteers in its clinical research, supporting evaluation of pharmacokinetics and basic safety profiles for its investigational compounds.
- Pharmacokinetics
- Drug interaction assessment
- Early clinical safety
These studies are relevant to understanding how candidate therapies behave in the body before use in disease-focused populations.
Therapeutic development with vonafexor
Across its trials, the sponsor’s main therapeutic interest is centered on vonafexor, with research spanning renal disease, metabolic liver disease, and early human evaluation of its salt form, EYP651.
- Vonafexor
- EYP651
- Renal and metabolic indications
The clinical program links targeted pharmacology with disease areas where renal and metabolic pathways are both relevant.
